Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Cash Flows From Operating Activities | |||||
Net Income | -2,556,000 | -4,170,000 | 5,613,000 | 4,196,000 | 2,024,000 |
Depreciation Amortization | 1,384,000 | 690,000 | 2,693,000 | 2,005,000 | 1,321,000 |
Income taxes - deferred | -889,000 | -723,000 | -962,000 | -592,000 | -524,000 |
Accounts receivable | -95,000 | -66,000 | 157,000 | -63,000 | 549,000 |
Accounts payable and accrued liabilities | -11,000 | 72,000 | -347,000 | -304,000 | -275,000 |
Other Working Capital | -2,005,000 | -459,000 | -2,303,000 | -1,760,000 | -211,000 |
Other Operating Activity | 7,716,000 | 6,875,000 | 3,155,000 | 2,355,000 | 1,198,000 |
Operating Cash Flow | $3,544,000 | $2,219,000 | $8,006,000 | $5,837,000 | $4,082,000 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 2,348,000 | 2,348,000 | -86,000 | -77,000 | -69,000 |
PPE Investments | -235,000 | -105,000 | -585,000 | -370,000 | -248,000 |
Net Acquisitions | -4,195,000 | -4,043,000 | -1,152,000 | -873,000 | -794,000 |
Purchase Of Investment | -444,000 | -410,000 | -442,000 | -218,000 | -192,000 |
Other Investing Activity | 12,000 | 3,000 | 0 | 0 | -6,000 |
Investing Cash Flow | $-2,514,000 | $-2,207,000 | $-2,265,000 | $-1,538,000 | $-1,309,000 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | N/A | 1,980,000 | 1,979,000 | N/A |
Debt Repayment | -1,851,000 | N/A | -2,250,000 | -2,250,000 | N/A |
Common Stock Issued | 151,000 | 146,000 | 232,000 | 206,000 | 123,000 |
Common Stock Repurchased | -500,000 | -400,000 | -1,000,000 | -850,000 | -550,000 |
Dividend Paid | -1,962,000 | -990,000 | -3,809,000 | -2,866,000 | -1,913,000 |
Other Financing Activity | -152,000 | -117,000 | -278,000 | -245,000 | -167,000 |
Financing Cash Flow | $-4,314,000 | $-1,361,000 | $-5,125,000 | $-4,026,000 | $-2,507,000 |
Exchange Rate Effect | -29,000 | -18,000 | 57,000 | 20,000 | 26,000 |
Beginning Cash Position | 6,085,000 | 6,085,000 | 5,412,000 | 5,412,000 | 5,412,000 |
End Cash Position | 2,772,000 | 4,718,000 | 6,085,000 | 5,705,000 | 5,704,000 |
Net Cash Flow | $-3,313,000 | $-1,367,000 | $673,000 | $293,000 | $292,000 |
Free Cash Flow | |||||
Operating Cash Flow | 3,544,000 | 2,219,000 | 8,006,000 | 5,837,000 | 4,082,000 |
Capital Expenditure | -235,000 | -105,000 | -585,000 | -370,000 | -248,000 |
Free Cash Flow | 3,309,000 | 2,114,000 | 7,421,000 | 5,467,000 | 3,834,000 |